Attached files
file | filename |
---|---|
8-K - 8-K - SYNERGY PHARMACEUTICALS, INC. | a17-14388_18k.htm |
Exhibit 99.1
Synergy Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
NEW YORK, May 30, 2017 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present a corporate update at the Jefferies Global Healthcare Conference in New York City on Thursday, June 8, 2017 at 2:00 p.m. Eastern Time.
A live webcast of the presentation will be accessible through the Investor Relations section of the companys website at www.synergypharma.com. A replay of the webcast will be available on Synergys website for 90 days following the conference.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Synergys proprietary GI platform includes one commercial product TRULANCE (plecanatide) and a second lead product candidate, dolcanatide. For more information, please visit www.synergypharma.com.
Company Contact:
Synergy Pharmaceuticals Inc.
Gem Hopkins, 212-584-7610
VP, Investor Relations and Corporate Communications
ghopkins@synergypharma.com